Ytterbium-169-phytate: A potential new radiopharmaceutical for functional scintigraphy of the liver

A new radiopharmaceutical for liver scintigraphy has been prepared by reacting 169YbOCl with Na phytate under conditions which yield a labelling efficiency of more than 99% over a wide pH range. In rabbits the resultant colloidal preparation shows a rapid elimination from the blood and high initial...

Full description

Saved in:
Bibliographic Details
Published in:The International journal of applied radiation and isotopes 1982-08, Vol.33 (8), p.673-677
Main Authors: Agha, N.H., Al-Hilli, A.M., Hassen, H.A., Al-Hissoni, M.H.S., Miran, K.M.
Format: Article
Language:English
Subjects:
Adult
Animals
Hepatomegaly - diagnostic imaging
Humans
Liver - diagnostic imaging
Male
Phytic Acid
Rabbits
Radiation Dosage
Radionuclide Imaging
Technetium
Technetium Compounds
Tin
Tin Compounds
Tissue Distribution
Ytterbium
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A new radiopharmaceutical for liver scintigraphy has been prepared by reacting 169YbOCl with Na phytate under conditions which yield a labelling efficiency of more than 99% over a wide pH range. In rabbits the resultant colloidal preparation shows a rapid elimination from the blood and high initial uptake in liver. Subsequently about 90% of the liver activity is lost within 3 days, the remainder being eliminated more slowly. The radiopharmaceutical is non-toxic and has a shelf-life of about 3 months. Scintigrams obtained in patients with hepatomegaly suggest that this new agent gives better visualization of space occupying lesions of the liver than 99 m TcSn colloid. The radiation dose to the patient from this agent is low and comparable with that from other radiopharmaceuticals used for liver scintigraphy.
ISSN:0020-708X
DOI:10.1016/0020-708X(82)90068-0